Detalhe da pesquisa
1.
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Proc Natl Acad Sci U S A
; 116(45): 22730-22736, 2019 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31624127
2.
PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
Gynecol Oncol
; 153(1): 158-164, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30630630
3.
Improved i.p. drug delivery with bioadhesive nanoparticles.
Proc Natl Acad Sci U S A
; 113(41): 11453-11458, 2016 10 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663731
4.
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.
Proc Natl Acad Sci U S A
; 113(43): 12238-12243, 2016 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27791010
5.
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
Gynecol Oncol
; 144(1): 146-152, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27894751
6.
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
Br J Cancer
; 115(3): 303-11, 2016 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27351214
7.
Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Am J Obstet Gynecol
; 214(1): 99.e1-8, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26272866
8.
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.
Proc Natl Acad Sci U S A
; 110(8): 2916-21, 2013 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359684
9.
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer.
Int J Cancer
; 137(11): 2618-29, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26060989
10.
Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
Cancer
; 121(3): 403-12, 2015 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25251053
11.
PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
Br J Cancer
; 113(7): 1020-6, 2015 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26325104
12.
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Tumour Biol
; 36(7): 5505-13, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25669172
13.
Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.
Gynecol Oncol
; 138(1): 11-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25931171
14.
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.
Gynecol Oncol
; 139(1): 112-7, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26260909
15.
Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Gynecol Oncol
; 135(2): 312-7, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25172762
16.
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Gynecol Oncol
; 135(1): 142-8, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-25124161
17.
Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in Solid Tumors.
Cancers (Basel)
; 16(6)2024 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38539548
18.
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Cell Rep
; 43(5): 114174, 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700982
19.
Tubulin-ß-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Cancer
; 119(14): 2582-92, 2013 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23585021
20.
HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
Gynecol Oncol
; 131(3): 753-8, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24012800